Serious Illness Communication Project

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Partners HealthCare
Charina Endowment Fund
Margaret T. Morris Foundation
Harvard School of Public Health
Brigham and Women's Hospital
Information provided by (Responsible Party):
Rachelle Bernacki, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01786811
First received: August 7, 2012
Last updated: February 23, 2015
Last verified: February 2015
  Purpose

The purpose of the study is to evaluate the impact of implementing a "Serious Illness Conversation Guide" to guide patient/family-clinician discussions and planning about end-of-life care decisions. The goal of the intervention is to improve achievement of patient care priorities and peacefulness at the end of life for patients with serious and life-threatening illness and their families. We hypothesize that patients whose physician is trained to use and adheres to the elements of the Serious Illness Conversation Guide will demonstrate enhanced consistency between documented key priorities and care received, and will experience greater peace in the final month of life; similarly, their families will experience higher satisfaction with care.


Condition Intervention
End of Life Care
Cancer
Behavioral: Training

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Serious Illness Communication Project

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Enhanced goal-consistent care [ Time Frame: up to 2 years ] [ Designated as safety issue: No ]
    Patients whose physician is trained to use and adheres to the SICG will receive care that is more consistent with their key life priorities during the last week and the last 3 months of life than patients whose physician is not trained to use the SICG. Goal consistent care will be measured by comparing goals identified by the patient during the final 3 months and final week of life, to care received by the patient, which will be measured by chart review and family report. For each priority/goal listed by the patient as important, we will give a score from 0 to 3 to quantify the extent to which that goal was achieved by the patient. Higher overall score will show more goal-consistent care.

  • PEACE [ Time Frame: up to 2 years ] [ Designated as safety issue: No ]
    Patients whose physician is trained to use and adheres to the SICG will be more likely to report being at peace in the final 3 months of life than patients whose physician is not trained to use the SICG. Being at peace will be measured by the PEACE scale, a 13-item validated questionnaire in cancer patients.


Estimated Enrollment: 1002
Study Start Date: June 2012
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Trained Clinicians
Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
Behavioral: Training
  1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on "Challenges in discussing advance care planning/values and goals" followed by practice using the SICG.
  2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person.
No Intervention: Non-trained Clinicians
Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
No Intervention: Non-volunteer Clinicians
These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

The subjects of this study will be the clinicians (physicians and nurse practitioners) conducting the SICG conversations, their patient with high-risk cancers, and a friend or family member of the patient.

Clinician Inclusion Criteria:

  1. Dana-Farber Cancer Institute medical oncology clinician
  2. Care for patients with selected high-risk cancers

Clinician Exclusion Criteria:

  1. DFCI Gynecology-Oncology specialist
  2. Seeing patients only in the Phase I clinical trial disease center

Patient Inclusion Criteria

  1. Over 18 years of age
  2. English speaker
  3. Patient at Dana-Farber Cancer Institute, including satellite sites at Milford Regional Medical Center and South Shore Hospital
  4. Diagnosis of one of the following high mortality or advanced cancers: breast, gastric, intestinal, esophageal, pancreatic, biliary, colorectal, hepatocellular, head and neck, renal, bladder, prostate, acute myeloid lymphoma (AML), acute lymphoblastic lymphoma (ALL), lymphoma, melanoma, glioblastoma multiforme (GBM), sarcoma, and lung.
  5. Ability to provide consent

Patient Exclusion Criteria

  1. Diagnosis of advanced obstetric-gynecological cancer
  2. Cognitive impairment

Family Member Inclusion Criteria

  1. Over 18 years of age
  2. English speaker
  3. Friend or family member of study patient (Health care proxy, or close friend or family member who is involved in helping the patient think about decisions related to their health care)
  4. Ability to provide consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01786811

Contacts
Contact: Mathilde M Hutchings, MPH 617-582-8871 mhutchings@partners.org
Contact: Joanna Paladino, MD 617-632-6055 jpaladino@partners.org

Locations
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Mathilde Hutchings, MPH    617-632-6055    mhutchings@partners.org   
Sponsors and Collaborators
Dana-Farber Cancer Institute
Partners HealthCare
Charina Endowment Fund
Margaret T. Morris Foundation
Harvard School of Public Health
Brigham and Women's Hospital
Investigators
Principal Investigator: Rachelle Bernacki, MD, MS Dana-Farber Cancer Institute
Principal Investigator: Atul Gawande, MD, MPH Harvard T. H. Chan School of Public Health
Principal Investigator: Susan Block, MD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Rachelle Bernacki, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT01786811     History of Changes
Other Study ID Numbers: 12-027
Study First Received: August 7, 2012
Last Updated: February 23, 2015
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on September 03, 2015